Tolaney SM, et al. - Authors assessed longer-term consequences to describe the biology of small human epidermal growth factor receptor 2 (HER2)–positive breast cancer and genetic factors predisposing to paclitaxel-induced peripheral neuropathy (TIPN) among 410 subjects recruited between October 2007 and September 2010. They noted 23 disease-free survival (DFS) events after a median follow-up of 6.5 years. They also recorded a 7-year DFS of 93% with four distant recurrences, a 7-year overall survival (OS) of 95%, and a 7-year recurrence-free interval (RFI) of 97.5%. They noted that the majority of tumors were HER2-enriched (66%), then luminal B (14%), luminal A (13%), and basal-like (8%). In those with grade 2 or greater TIPN (10.4%), an association of rs3012437 (single-nucleotide polymorphism identified by genotyping) was seen with a higher risk of TIPN. They observed a relationship between adjuvant paclitaxel and trastuzumab and excellent long-term outcomes in the longer follow-up.